Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis

SGLT-2 inhibitors were associated with a 31% lower risk of heart failure hospitalization compared to glucagon-like peptide-1 receptor agonists.

• SGLT-2 inhibitors did not significantly reduce major adverse cardiovascular events compared to other treatments.
• They were linked to a significantly lower risk of composite renal outcomes compared to glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists.
• Compared to glucagon-like peptide-1 receptor agonists, SGLT-2 inhibitors reduced heart failure hospitalization by 31%.
• Compared to non-steroidal mineralocorticoid receptor antagonists, SGLT-2 inhibitors reduced heart failure hospitalization by 22%.
• No significant differences were observed between glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists for any outcomes.

AI simplified